All attending UK organisations
UK companies registered through BioPartner UK to attend BIO Convention 2023:
(Click here to search profiles)
Almac Discovery, Aptamer Group, Arecor, Axol Bioscience, Barrington James, Bit Bio, C4X Discovery, Cell Guidance Systems, CLINICAL ACCELERATOR, Crescendo Biologics, Cresset, CrystecPharma, DLRC, Elasmogen, Epitopea, Etcembly, Evgen Pharma, Fair Journey Biologics, Fusion Antibodies, Galecto Biotech, Hippocampus Pharma, HistologiX, hVIVO, Imophoron, Intract Pharma, LSX, Mereo BioPharma, Mursla Bio, Nucleic Acid Therapy Accelerator, Oppilotech, Ori Biotech, PharmaVentures, PrecisionLife, Remap Consulting, Ribonexus, Rosemont Pharmaceuticals, Sareum, SBA, Seda Pharmaceutical Development Services, Sekisui, Silence Therapeutics, Stemnovate, Therakind, Ubiquigent, UK BioIndustry Association (BIA), Viramal, VirdisGroup.
UK Exhibitors
Almac Group Booth 1969, Barrington James Booth 2542, Sekisui Booth 778
Abzena, Bird & Bird, Genetic-Microdevices, Random42, RBW Consulting, Symbiosis Pharmaceutical Services, Vectura
UK Pavilion and Regional Groups:
G&L Healthcare Advisors, Integrity, Invest Northern Ireland, MEU, Micropore Technologies, OBN, ONIX Life Sciences, Oribiotech, Pangaea, Phaim, Scottish Development International, Seda, Touchlight, UKRI - STFC, Welsh Government.
As also listed here.
All attending UK companies:
abcam, Abel & Imray, Accession Therapeutics, Accord Healthcare, Adaptimmune, ADVANZ Pharma, AilseVax, Airfinity, Alan Boyd Consultants, Alchemab Therapeutics, Allucent, Almac Discovery, Alvogen UK, AMPLY Discovery, Anestpharma, Antev, Antibody Analytics, Antiverse, Apex Healthcare Consulting, Apollo Therapeutics, Aptamer Group, Arecor, ARS-Patent, AstraZeneca, Autolus Therapeutics, Avacta Therapeutics, Axol Bioscience, Barker Brettell, Barrington James, Bartle Read, Basecamp Research, Baseimmune, BDD Pharma, BenevolentAI, Bicycle Therapeutics, Biocell, Biodexa Pharmaceuticals, BioPartner UK, bit bio, Bitesize Bio, BlokBio, Boult Wade Tennant, Brand Murray Fuller, C4X Discovery, Cambridge Enterprise, Cambridge Enterprise, Cambridge Innovation Capital, Cambridge Innovation Capital, Cambridge Respiratory Innovations, Canaccord Genuity, Cancer Research UK, Cardiff University, Cell and Gene Therapy Catapult, Cell Guidance Systems, Centessa Pharmaceuticals, CGT Catapult, Charles River Laboratories, Charnwood Molecular, ChronosDx, Chugai Pharmaceutical Co., Clinical Accelerator, Clinigen Group, CN Bio Innovations, Coalition for Epidemic Preparedness Innovations, Crescendo Biologics, Cresset, Crystec Pharma, Cumulus Neuroscience, CV6 Therapeutics (NI), Cytiva (formerly known as GE Healthcare), DBounce, Deep Science Ventures, Dehns, Destiny Pharma, DLRC, Dxcover, Eip, Elasmogen, Ellipses Pharma, EMD Serono, EnteroBiotix, EOs Deal advisory, Epitopea, Etcembly, e-therapeutics, Evaluate, Evariste, Eversheds Sutherland, Evgen, Evox Therapeutics, Exeter University, Exscientia, FirstWord Group, Fitabeo Therapeutics, Fusion Antibodies, George Medicines, Gill Jennings & Every, Glenmark Pharmaceuticals, Globalbrain, GOWLING WLG, Grunenthal, GSK, Harwell Campus, Healx, Heptares Therapeutics, HGF, Hippocampus Pharma, HistologiX, HitGen, Huma, hVIVO, IBioIC, IDEA Regulatory, Iksuda Therapeutics, ILC Therapeutics, Immodulon, Imophoron, Impact IP, Industrial Biotechnology Innovation Centre, Ingenza, Innovation Ulster, IN-PART, Intract Pharma, Ipsen, IQVIA, Isomorphic Labs, J A Kemp, Johnson & Johnson, Johnson & Johnson Innovation, Kilburn & Strode, King's College London, Kynos Therapeutics, Kyowa Kirin International, LabCorp, LabGenius, Lead Candidate, LEHVOSS UK, Life Sciences Recruitment, LifeArc, Lifescience Dynamics, LiliumX, Liminal Biosciences Inc., Lindus Health, LSX Leaders, M:M Bio, Mantell Associates, McDermott Will & Emery, Medicines Discovery Catapult, Merck, Mereo BioPharma Group, Mesenbio, Mewburn Ellis, Mills & Reeve, Mindrank, Mitsubishi Tanabe Pharma Corporation, Morgan Prestwich, MSD European Innovation Hub, Murgitroyd & Company, Mursla Bio, Nanosyrinx, NDA Group, NeoPhore, Norgine, Novateur Ventures Inc., Novumgen, NRG Therapeutics, Nucleome Therapeutics, NunaBio, Nuntius Therapeutics, Oak Hill Bio, Ochre Bio, OES, OMass Technologies, One Nucleus, Oppilotech, Orbit Discovery, Ori Biotech, Osborne Clarke, Oxford BioMedica, Oxford BioTherapeutics, Page White and Farrer, European Patent Attorneys, Pall Biotech, Pathios Therapeutics, Pearl Bio, Peptone, Perfectus Biomed, Pharmanovia, PharmaVentures, PharmEnable, Phion Therapeutics, PhoreMost, Pneumagen, PrecisionLife, ProAxsis, Quadram Institute Bioscience, Queens University Belfast, Quell Tx, Quotient Sciences, ramarketing, Reddie & Grose, Relation Therapeutics, Remap Consulting, ReNewVax, Results Healthcare, Ribonexus, Rosemont Phamaceuticals, Roslin Cell Therapies, RPC, RQ Biotechnology, Sareum, SBA, Scancell Holdings, Scarlet Therapeutics, Scendea, Sciensus, Scottish Brain Sciences, Scottish Development International, Seda Pharmaceutical Development Services, SEKISUI, Serac Healthcare, Sharpview Ophthalmology, Shionogi & Co., Silence Therapeutics, Simbec-Orion, Simcere Pharmaceutical Group, Sonrai Analytics, Stemnovate, Stephenson Harwood, Stifel, Storm Therapeutics, Sulantrix, SVMPharma, SYMBIOSIS IP, Tay Therapeutics, Terrapinn, Texere Publishing, The Institute of Cancer Research, The Wellcome Trust, Theolytics, Therakind, ThirtyFiveBio, TotalLab, Touchlight DNA Services, TranScrip, Transine Therapeutics, Treehill Partners, Trisk Bio, Tumour BioSciences, Ubiquigent, UCB SA, UK Bioindustry Association (BIA), UK Government - Department for Business and Trade, UKRI - STFC, University of Bath, University of Birmingham, University of Leeds, University of Manchester Innovation Factory, Venner Shipley, Virdisgroup, ViroCell Biologics, Virtus Respiratory Research, Weatherden, Wellcome Trust, WP Thompson, Wyoming Interactive (265)
